Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple vs Dual Adjuvant Therapy in VETC-positive HCC
NCT06311942Phase 4Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Disease-Free Survival at 60 months. Started Apr 2024; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06311942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311942.